Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
HOWL Stock Chart & Stats
$0.98
-$0.04(-2.90%)
At close: 4:00 PM EST
$0.98
-$0.04(-2.90%)
Day’s Range― - ―
52-Week Range$0.60 - $2.38
Previous CloseN/A
Volume113.58K
Average Volume (3M)1.22M
Market Cap
$55.33M
Enterprise Value$8.58M
Total Cash (Recent Filing)$65.71M
Total Debt (Recent Filing)$37.30M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 19, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding45,729,000
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.87
Price to Sales (P/S)34.02
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.31
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$9.00Price Target Upside818.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Investor InterestPhase 1 dose-expansion outcomes with Werewolf's tumor-conditional IL-2, WTX-124, are expected to drive investor interest.
Pipeline EvolutionWerewolf's latest update marks a clear step forward in the evolution of its pipeline, with progress across all three of its active programs.
Regulatory EngagementWerewolf plans to engage with regulatory authorities to discuss potential registrational pathways for WTX-124 in advanced cutaneous melanoma.
Bears Say
Dataset ConcernsThe primary question now is whether WTX-124’s interim dataset will deliver the depth and durability of response necessary to anchor a registrational program in melanoma.
Investor SkepticismThe bar for excitement is high—20-30% confirmed overall response rates in 20-30 patients—due to persistent investor skepticism toward IO mechanisms.
Werewolf Therapeutics News
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.59 and its highest was $2.38 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $55.33M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 113 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.383 by $0.023.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 45,729,000 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.383. Following the earnings report the stock price went down -7.634%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
Werewolf Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (818.37% Upside)
$9.00 (818.37% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.95%
12-Months-Change
Fundamentals
Return on Equity
-122.43%
Trailing 12-Months
Asset Growth
-39.78%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics (HOWL) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company specializes in a proprietary platform that combines targeted therapeutics with its unique drug delivery systems to enhance the efficacy of treatments while minimizing side effects. With a strong emphasis on research and development, Werewolf Therapeutics aims to address unmet medical needs through its advanced therapeutic solutions.
HOWL Stock 12 Month Forecast
Average Price Target
$9.00
▲(818.37% Upside)
Technical Analysis
CervoMed
―
NRX Pharmaceuticals
―
Kalaris Therapeutics
―
Coeptis Therapeutics Holdings
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
48.95% Insiders
3.44% Mutual Funds
31.45% Other Institutional Investors
13.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---